drugset / Trial / NCT07653581
rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 3 mg/kg | — |
| Subject | Cyclosporine | Peptide | 5 mg/kg | — |
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 300 iu/kg | Subcutaneous |